All the excitement about Mobvoi and the upcoming launch, it's easy to forget the news that we had on our commercial contract with Andon and the resultant upcoming launch of Atcor Pulse ,a new home-use based device based on ATCOR’s patented and global standard SphygmoCor® technology for measuring central blood pressure and arterial stiffness.
Our first contracted order of the Pulse will be ~10,000 units.
Craig said in the December business update :
"As a guide to the impact of this new device on the revenues for the Company, our current device sales of the XCEL central blood pressure monitor (which constitutes the most significant portion of our sales)are in the low hundreds annually.Volume sales of our new devices targeting the consumer market are anticipated to be exponentially higher based on our internal market forecasts and anticipated product demand."
This alone will fundamentally change the P&L for Cardiex.
The pricing is unknown, but a top end home BP monitor retails for AUS $160,
For the purpose of this quick, back of the envelope calculation, let's say priced at $100 wholesale per unit from Andon to retailers for ATCOR Pulse
Our % share of this , say 20% ( conservative ? ). So $20 per unit.
10,000 units = $200,000, high margin sales already locked away.
Craig says exponentially higher sales volume. No sure what that means actually, but let's go for 50x, so 500,000 units for first year full year sales.
$20 ea - $10M sales.
Even half of that would make a material difference to the P&L.
Oh, and then there is the Mobvoi Smart Watch launch.
Add to My Watchlist
What is My Watchlist?
